---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274183"
form_type: "8-K"
ticker: "KMTS"
cik: "0001877184"
company_name: "KESTRA MEDICAL TECHNOLOGIES, LTD."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:39:10.227225+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kestra's ASSURE wearable defibrillator achieves 100% conversion in largest real-world study

## Summary
- 21,612-patient ACE-PAS trial met primary effectiveness endpoint: 100% successful conversion for VT/VF events.
- Inappropriate-shock rate of 0.0065 per patient-month, below prespecified safety performance goal.
- 94% of patients experienced no false positive shock alarms; median wear time >23 hours per day.
- 2.6% of patients had at least one life-threatening VT/VF event, highlighting early risk.
- Results presented as late-breaking science at AHA Scientific Sessions 2025.

## SEC filing metadata
- accession: 0001193125-25-274183
- form_type: 8-K
- ticker: KMTS
- cik: 0001877184
- company_name: KESTRA MEDICAL TECHNOLOGIES, LTD.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/0001193125-25-274183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877184/000119312525274183/ck0001877184-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274183
- JSON: https://secwatch.observer/filing/0001193125-25-274183.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.